|
|
Article: Regeneron Secures License To Artemis Gene-Switch Technology.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Regeneron Pharmaceuticals Inc. gained rights to a gene-switch technology from Artemis Pharmaceuticals GmbH in an effort to discover new therapies and build its pipeline.
The nonexclusive sublicense grants Tarrytown, N.Y.-based Regeneron the ability to use Artemis' gene-switch technology based on ligand-regulated DNA recombination, but only for internal research.
"This is a general license, which is not bound to a certain indication area or disease area," said Peter Stadler, managing director of Cologne, Germany-based Artemis. "This is a technology license, which they can use in whatever area that they want to in their ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|